Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Operating Expenses for the year ending April 30, 2023: USD 110.07 M

Kalvista Pharmaceuticals Inc Operating Expenses is USD 110.07 M for the year ending April 30, 2023, a 14.81% change year over year. Operating Expenses refer to the ongoing expenses incurred by a company in its day-to-day operations, including salaries, rent, utilities, and other administrative costs.

Kalvista Pharmaceuticals Inc Operating Expenses for the year ending April 30, 2022 was USD 95.87 M, a 37.03% change year over year.
Kalvista Pharmaceuticals Inc Operating Expenses for the year ending April 30, 2021 was USD 69.96 M, a 31.55% change year over year.
Kalvista Pharmaceuticals Inc Operating Expenses for the year ending April 30, 2020 was USD 53.18 M, a 15.75% change year over year.
Kalvista Pharmaceuticals Inc Operating Expenses for the year ending April 30, 2019 was USD 45.95 M, a 69.55% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends